AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03152500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEMTIS 313G IOL
Description: Haptic design that enclaves the capsulorrhexis
Study NCT03152500 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acrysof SN60WF IOL
Description: IOL in the bag
Study NCT02867371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Archimedes System
Description: The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
Study NCT03753750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive spinal cord stimulation
Description: Noninvasive spinal cord stimulation is a transcutaneous technique used to modulate the activity of the spinal cord. Subjects will undergo sham or actual stimulation 3-4 times a week for one hour at a time.
Study NCT03753750 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Noninvasive spinal cord stimulation
Description: Noninvasive spinal cord stimulation is a transcutaneous technique used to modulate the activity of the spinal cord. Subjects will undergo sham or actual stimulation 3-4 times a week for one hour at a time.
Study NCT00397202 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diva Cup TM
Description: See Detailed Description.
Study NCT01494740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, non-adjuvanted vaccine of 7.5 μg
Description: 120 infants were assigned to receive 2 dose of 7.5μg split-virion, non-adjuvanted H1N1 vaccine.
Study NCT01494740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, non-adjuvanted H1N1 vaccine of 15 μg
Description: 120 infants were assigned to receive 2 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
Study NCT01494740 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: split-virion, non-adjuvanted vaccine of seasonal influenza
Description: 120 infants were assigned to receive 2 dose of split-virion, non-adjuvanted seasonal influenza vaccine.
Study NCT03991013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a matching placebo taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
Study NCT02940093 — intervention group
Intervention type: OTHER
Intervention: Stem cell transplantation
Description: Intervention is not conducted as part of the study but patients at Tübingen University Hospital undergoing this intervention as part of their standard care are being monitored in this observational study.
Study NCT03104400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered by subcutaneous injection
Study NCT03104400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Oral tablet
Study NCT03104400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablet
Study NCT03104400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Upadacitinib
Description: Oral tablet
Study NCT03104400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Upadacitinib
Description: Oral tablet
Study NCT03104400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Adalimumab
Description: Administered by subcutaneous injection
Study NCT03104400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Adalimumab
Description: Administered by subcutaneous injection
Study NCT05131087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cadence implant
Description: CADENCE Glaucoma Drainage Device System is a single use implantable glaucoma drainage device used for the surgical treatment of refractory glaucoma. The device is implanted in the eye using an ab-externo approach
Study NCT00242203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zometa
Study NCT00242203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Study NCT00242203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT00242203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT00242203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT00242203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: ONLY for patients that are Her-2 overexpressing by 3+ by ICH for FSH
Study NCT00242203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: ONLY for patients that are Her-2 overexpressing by 3+ by ICH for FSH
Study NCT00242203 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation
Study NCT02223507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIR 561 CL
Study NCT02223507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00242203 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation
Study NCT00242203 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection
Study NCT00242203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection
Study NCT01421589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Description: Growth hormone 0.4 mg once daily (titrated to IGF-1) by sub-cutaneous injection for 12 weeks.
Study NCT03790514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Heat Wrap
Description: Commercially heat tapes ( without drugs) will be applied to patients.
Study NCT03790514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat Wrap
Description: Commercially heat tapes ( without drugs) will be applied to patients.
Study NCT01082172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant Thoracic Stent Graft
Description: Endovascular implant of Thoracic Aortic Aneurysm Stent Graft
Study NCT04204772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated charcoal and Tap Water
Description: 12 grams of AC mixed with Tap water or 25 grams of AC mixed with Tap water
Study NCT04204772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated Charcoal and Apple Juice
Description: 12 grams of AC with Apple Juice or 25 grams of AC with Apple Juice
Study NCT02676323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat will be given orally (PO) on days 1, 3, 5, 8, 10, and 12.
Study NCT02676323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given intravenously (IV), 30 mg/m\^2/dose over 30 minutes, daily for 5 days (days 8-12).
Study NCT02676323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine will be given IV, 2 gram/m\^2/dose over 4 hours, daily for 5 days (days 8-12).
Study NCT02676323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triples
Description: Given intrathecally (IT).
Study NCT02676323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin (5 mg/m\^2/dose, max 5 mg) may be given PO or IV at 24 and 30 hours after each ITMHA.
Study NCT00464919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study NCT00464919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur/uracil (UFUR®)
Study NCT03257423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem followed by levofloxacin and metronidazole
Description: Ertapenem 1 g i.v. daily for either 2 days (MAPPAC + APPAC II patients) or 3 days (MAPPAC + APPAC III) followed by p.o. levofloxacin 500 mg x 1 + metronidazole 500 mg x 3 for either 5 days (APPAC II + MAPPAC) or 4 days (APPAC III + MAPPAC)
Study NCT03257423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg once a day for seven days (APPAC II + MAPPAC)
Study NCT03257423 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Appendectomy
Description: Primarily laparoscopic appendectomy for either complicated acute appendicitis or uncomplicated acute appendicitis (refusing to participate in APPAC II or III trials or recurrent acute appendicitis).
Study NCT04943809 — intervention group
Intervention type: DEVICE
Intervention: POD 26P AY F
Description: Routine cataract surgery
Study NCT03081767 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital PET/CT scan
Description: The Division of Nuclear Medicine and Molecular Imaging at Stanford has installed the first ever GE-made digital PET/CT scanner worldwide. The investigators wish to determine if the digital PET/CT scanner offers equivalent image quality as the standard PET/CT scanner.
Study NCT01578174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -> 2㎍/mL) : the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
Study NCT01578174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal saline 100mL(guess as 2㎍/mL):the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
Study NCT00820456 — intervention group
Intervention type: OTHER
Intervention: DCE-MRI
Description: Participants will receive two (2) dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) prior to chemotherapy and one (1) DCE-MRI after the first cycle of chemotherapy. Participants will be followed for up to 2 years after the initiation of chemotherapy or until disease progression.
Study NCT02699580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lateral rectus recession with biodegradable collagen implant
Description: Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done. After lateral rectus recession, no degradable collagen implant was placed in the area, where lateral rectus was original inserted. One eye was randomly selected for the comparison.
Study NCT03257423 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo i.v. once a day for three days (APPAC III + MAPPAC) followed by placebo capsules three times a day for four days.
Study NCT01731587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: MUC1 peptide specific immunotherapy
Description: Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals, commencing at Week 14, until disease progression is documented.
Study NCT01731587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPA)
Description: A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.
Study NCT02632019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study NCT02699580 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral rectus recession without biodegradable collagen implantation
Description: Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done in the other eye without placing biodegradable collagen implantation.
Study NCT02632019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study NCT02632019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell-precision T cell for neo-antigen combined with gemcitabine treatment
Description: Gemcitabine: Gemcitabine 1000mg/m2, Physiological saline 100ml: IV (in the vein) once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.~PNAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study NCT02249884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea Dose A
Description: Urea cream for topical use.
Study NCT02249884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea Dose B
Description: Urea cream for topical use.
Study NCT00003143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Study NCT00003143 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DHAP
Study NCT00003143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHAP
Study NCT00128622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denileukin diftitox
Study NCT01647191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention group
Description: The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
Study NCT01647191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: The investigators will adopt previous treatment in the clinics to intervent the patients
Study NCT01607229 — intervention group
Intervention type: OTHER
Intervention: observation
Description: no intervention used, observed measurements from 3 test devices compared to reference criterion measurement for total body water and body composition
Study NCT01566942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: In this arm, patients will receive the adjuvant chemotherapy with mFOLFOX6 regimen for 8 cycles. Oxaliplatin 85mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
Study NCT00128622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Study NCT00128622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Study NCT01170884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution
Description: 1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (Combigan®) taken approximately 12 hours apart, up to 2 times a day and 1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken once every 24 hours.
Study NCT01170884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
Description: 1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken approximately every 24 hours; mild lubricant eyedrops (Gen Teal® Mild) for masking purposes
Study NCT02487940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
Study NCT02487940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
Study NCT04175353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy snack
Description: The effects of dairy snack are compared with orange juice.
Study NCT04175353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy snack
Description: The effects of dairy snack are compared with orange juice.
Study NCT04175353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry snack
Description: The effects of two berry snacks are compared with berry soup.
Study NCT04175353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berry snack
Description: The effects of two berry snacks are compared with berry soup.
Study NCT02249884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea Dose C
Description: Urea cream for topical use.
Study NCT02249884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chamomile Dose A
Description: Chamomile gel for topical use.
Study NCT02249884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chamomile Dose B
Description: Chamomile gel for topical use.
Study NCT02249884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chamomile Dose C
Description: Chamomile gel for topical use.
Study NCT02730715 — intervention group
Intervention type: DRUG
Intervention: Basiliximab
Description: Periodic blood collection to monitor Treg cells
Study NCT02730715 — intervention group
Intervention type: DRUG
Intervention: Thymoglobulin
Description: Periodic blood collection to monitor Treg cells
Study NCT04384172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tibial e-stim
Description: For tibial nerve stimulation, the two electrodes will be placed just above the medial malleolus and the ipsilateral calcaneus on one leg near the ankle.
Study NCT04384172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genital e-stim
Description: For dorsal genital nerve stimulation, two electrodes will be placed on either side of the clitoris.
Study NCT04188483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium Supplementation
Description: The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days.
Study NCT04188483 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza vaccination
Description: Subjects will receive standard seasonal influenza vaccination for the 2019-2020 season.
Study NCT02337933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolic acid
Description: Ursolic acid capsules of 150 mg extracted from rosemary, once a day before breakfast
Study NCT02337933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Calcined magnesia capsules of 150 mg, once a day before breakfast
Study NCT03554096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-HOBA
Description: 2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
Study NCT04299854 — intervention group
Intervention type: DRUG
Intervention: Dinoprostone 10mg
Description: Vaginal delivery system containing 10mg of dinoprostone placed at the bottom of the vagina
Study NCT04299854 — intervention group
Intervention type: DEVICE
Intervention: single balloon Foley catheter
Description: A single balloon Foley catheter is being inserted on transcervical and inflated above the internal cervical os
Study NCT04606563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Oral losartan 25 mg, stepped up to 50 mg and then up to 100 mg peak dose, as tolerated.
Study NCT04606563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Oral Valsartan 40 mg, stepped up to 80 mg and then up to 160 mg peak dose, as tolerated.
Study NCT04606563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Oral Azilsartan 40 mg, and stepped up to 80 mg.
Study NCT04606563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Oral Candesartan 8 mg, stepped up to 16 mg and then up to 32 mg peak dose, as tolerated.
Study NCT04606563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprosartan
Description: Oral Eprosartan 400 mg, stepped up to 600 mg and then up to 800 mg peak dose, as tolerated.
Study NCT04606563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Oral Irbesartan 75 mg, stepped up to 150 mg and then up to 300 mg peak dose, as tolerated.
Study NCT04606563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan
Description: Oral Olmesartan 10 mg, stepped up to 20 mg and then up to 40 mg peak dose, as tolerated.
Study NCT04606563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Oral Azilsartan 40 mg, and stepped up to 80 mg.
Study NCT00803959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Office evaluation
Description: Office evaluation